Around 100,000 medical professionals have registered to learn breast cancer related information through Zhongchao Inc.’s Breast Cancer Tiered Diagnosis and Treatment Improvement Platform in the first half of 2021. It marks one of the earliest efforts conducted for the Healthy China 2030 Guidelines, which aims to increase the overall five-year cancer survival rate by 15% by 2030.

Eli Lilly and Co. has established a multiyear collaboration with Kumquat Biosciences Inc. for the discovery, development and commercialization of new small molecules for stimulating tumor-specific immune responses. Kumquat will receive $70 million up front, including an equity investment, and is eligible for more than $2 billion in potential milestone payments plus royalties on any marketed products.